keyword
MENU ▼
Read by QxMD icon Read
search

Etanercept and kawasaki

keyword
https://www.readbyqxmd.com/read/24261768/the-role-of-tnf-%C3%AE-in-a-murine-model-of-kawasaki-disease-arteritis-induced-with-a-candida-albicans-cell-wall-polysaccharide
#1
Toshiaki Oharaseki, Yuki Yokouchi, Hitomi Yamada, Hiroshi Mamada, Satoshi Muto, Kiyomi Sadamoto, Noriko Miura, Naohito Ohno, Tsutomu Saji, Shiro Naoe, Kei Takahashi
OBJECTIVES: Various inflammatory cytokines, including tumor necrosis factor-α (TNF-α), have been reported to play roles in Kawasaki disease (KD). Recently, anti-TNF-α therapy was reported to show efficacy in patients who do not respond to high-dose intravenous immunoglobulin therapy. However, there are many gaps in our understanding of the role that TNF-α plays in the development of KD arteritis as well as whether anti-TNF-α therapy causes any histological changes in the arteritis...
January 2014: Modern Rheumatology
https://www.readbyqxmd.com/read/23606968/etanercept-suppresses-arteritis-in-a-murine-model-of-kawasaki-disease-a-comparative-study-involving-different-biological-agents
#2
Ryuji Ohashi, Ryuji Fukazawa, Makoto Watanabe, Hanako Tajima, Noriko Nagi-Miura, Naohito Ohno, Shinichi Tsuchiya, Yuh Fukuda, Shunichi Ogawa, Yasuhiko Itoh
Coronary arteritis, a complication of Kawasaki disease (KD), can be refractory to immunoglobulin (IVIG) treatment. To determine the most effective alternative therapy, we compared the efficacy of different agents in a mouse model of KD. Vasculitis was induced by injection of Candida albicans water-soluble fractions (CAWS) into a DBA/2 mouse, followed by administration of IVIG, etanercept, methylprednisolone (MP), and cyclosporine-A (CsA). At 2 and 4 weeks, the mice were sacrificed, and plasma cytokines and chemokines were measured...
2013: International Journal of Vascular Medicine
https://www.readbyqxmd.com/read/23529573/the-role-of-tnf-%C3%AE-in-a-murine-model-of-kawasaki-disease-arteritis-induced-with-a-candida-albicans-cell-wall-polysaccharide
#3
Toshiaki Oharaseki, Yuki Yokouchi, Hitomi Yamada, Hiroshi Mamada, Satoshi Muto, Kiyomi Sadamoto, Noriko Miura, Naohito Ohno, Tsutomu Saji, Shiro Naoe, Kei Takahashi
OBJECTIVES: Various inflammatory cytokines, including tumor necrosis factor-α (TNF-α), have been reported to play roles in Kawasaki disease (KD). Recently, anti-TNF-α therapy was reported to show efficacy in patients who do not respond to high-dose intravenous immunoglobulin therapy. However, there are many gaps in our understanding of the role that TNF-α plays in the development of KD arteritis as well as whether anti-TNF-α therapy causes any histological changes in the arteritis. Accordingly, the present histopathological study was carried out to elucidate the inhibitory effect of anti-TNF-α therapy on vasculitis as well as the role of TNF-α in the development of vasculitis in a murine model of KD vasculitis...
March 26, 2013: Modern Rheumatology
https://www.readbyqxmd.com/read/23283289/advances-in-the-treatment-of-kawasaki-disease
#4
REVIEW
Samuel R Dominguez, Marsha S Anderson
PURPOSE OF REVIEW: Intravenous immunoglobulin (IVIG) and aspirin is the standard initial therapy in the treatment of Kawasaki disease. Some patients have persistent or recrudescent fever despite this therapy. Although there is no conclusive body of evidence defining the best second and third-line therapies for Kawasaki patients, there have been several recent studies published describing the results of these therapies. RECENT FINDINGS: This review summarizes the current recommendations for the initial therapy and describes the second and third-line therapies studied in Japan and the United States...
February 2013: Current Opinion in Pediatrics
https://www.readbyqxmd.com/read/22613074/enhanced-susceptibility-to-lipopolysaccharide-induced-arthritis-and-endotoxin-shock-in-interleukin-32-alpha-transgenic-mice-through-induction-of-tumor-necrosis-factor-alpha
#5
Masanori Nakayama, Yasuo Niki, Toshiki Kawasaki, Yuki Takeda, Keisuke Horiuchi, Aya Sasaki, Yasunori Okada, Kazuo Umezawa, Hiroyasu Ikegami, Yoshiaki Toyama, Takeshi Miyamoto
INTRODUCTION: The present study assessed the potential functions of interleukin (IL)-32α on inflammatory arthritis and endotoxin shock models using IL-32α transgenic (Tg) mice. The potential signaling pathway for the IL-32-tumor necrosis factor (TNF)α axis was analyzed in vitro. METHODS: IL-32α Tg mice were generated under control of a ubiquitous promoter. Two disease models were used to examine in vivo effects of overexpressed IL-32α: Toll-like receptor (TLR) ligand-induced arthritis developed using a single injection of lipopolysaccharide (LPS) or zymosan into the knee joints; and endotoxin shock induced with intraperitoneal injection of LPS and D-galactosamine...
2012: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/21392603/etanercept-as-adjunctive-treatment-for-acute-kawasaki-disease-study-design-and-rationale
#6
RANDOMIZED CONTROLLED TRIAL
Michael A Portman, Aaron Olson, Brian Soriano, Nagib Dahdah, Richard Williams, Edward Kirkpatrick
BACKGROUND: Kawasaki disease (KD) is a multisystem vasculitis affecting coronary arteries in children. Patients, refractory to standard treatment with intravenous immunoglobulin and aspirin, show higher rates of coronary artery dilation. Early tumor necrosis factor α receptor antagonism in KD may provide effective adjunctive therapy. STUDY DESIGN: The EATAK trial is a multicenter, double-blind, randomized, and placebo-controlled trial intended to assess the efficacy of etanercept in reducing the intravenous immunoglobulin refractory rate during treatment of acute KD...
March 2011: American Heart Journal
https://www.readbyqxmd.com/read/20667551/prospective-open-label-trial-of-etanercept-as-adjunctive-therapy-for-kawasaki-disease
#7
Nadine F Choueiter, Aaron K Olson, Danny D Shen, Michael A Portman
OBJECTIVE: To determine the safety and pharmacokinetics of etanercept (Amgen, Thousand Oaks, California) a tumor necrosis factor-α receptor blocker, in children with acute Kawasaki disease (KD). Standard therapy of acute KD includes intravenous immunoglobulin (IVIG) and high-dose aspirin, but a substantial number of patients are refractory and require additional treatment. Tumor necrosis factor-α levels are elevated in children with KD, suggesting a role for etanercept in treatment...
December 2010: Journal of Pediatrics
https://www.readbyqxmd.com/read/16670341/tnf-alpha-is-necessary-for-induction-of-coronary-artery-inflammation-and-aneurysm-formation-in-an-animal-model-of-kawasaki-disease
#8
Joyce S Hui-Yuen, Trang T Duong, Rae S M Yeung
Kawasaki disease is the most common cause of multisystem vasculitis in childhood. The resultant coronary artery lesions make Kawasaki disease the leading cause of acquired heart disease in children in the developed world. TNF-alpha is a pleiotropic inflammatory cytokine elevated during the acute phase of Kawasaki disease. In this study, we report rapid production of TNF-alpha in the peripheral immune system after disease induction in a murine model of Kawasaki disease. This immune response becomes site directed, with migration to the coronary arteries dependent on TNF-alpha-mediated events...
May 15, 2006: Journal of Immunology: Official Journal of the American Association of Immunologists
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"